AACHEN, Germany, October 20, 2014 /PRNewswire/ --
Sascha Becker will be appointed to the Executive Board of the pharmaceutical company Grünenthal and take over the finance unit as Group Chief Financial Officer in the first quarter of 2015. Since 2003, Sascha Becker (43) has been working for Merck and is currently CFO of the biopharmaceutical division of Merck Serono with an annual turnover of 6.3 billion Euros and is responsible for 10,000 employees. At Grünenthal, he will succeed Stefan Genten whose contract terminates at the end of 2014.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company in the field of pain and thus to be a leader in therapy innovation.
Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 27 percent of revenues in 2013. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group has affiliates in 25 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2013, Grünenthal achieved revenues of €901 mn.
More information: http://www.grunenthal.com.
Contact: Friederike Herrfurth, Senior Director Communications, Tel.: +49-241-569-1335, Friederike.email@example.com
Grünenthal GmbH, 52099 Aachen, Germany
SOURCE Grunenthal Pharma GmbH & Co. KG.